Golden Tip
Novanta (NOVT)
Expected Upside: 16.7%
Target period: 6 Months
Publication Price
142.25
Target Price
166
- Accelerated organic growth and Riverpoint’s high-margin medical consumables could lift earnings and support a rerating of the valuation.
- Main Risk: Setbacks in the Riverpoint integration or weaker OEM demand could undermine expected earnings growth and compress Novanta’s premium valuation.
- Second-quarter 2026 organic revenue grew 9.3%, adjusted EBITDA rose 16.4%, and free cash flow reached $57.5 million. Management guides to $3.68-$3.74 adjusted EPS for 2026, while limited analyst consensus expects $4.37 in 2027. P/E and EV/EBITDA cross-checks support the $166 estimate, with upcoming results offering rerating catalysts.
The Golden Tip is a general investment recommendation, not personalized investment advice. Past performance and forecasts do not guarantee future results. It was prepared with the assistance of a third-party provider, subject to review and validation by the 50K Research Team. It does not take into account your portfolio, financial situation, investment objectives, risk tolerance, investment knowledge or experience, ability to bear losses, or trading history. Please always do your own research. Your capital is at risk.
